EP0453210A2 — Pyridine derivatives
Assigned to AstraZeneca AB · Expires 1991-10-23 · 35y expired
What this patent protects
The invention concerns pharmaceutically useful novel compounds of the formula I, in which R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositio…
USPTO Abstract
The invention concerns pharmaceutically useful novel compounds of the formula I, in which R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.